Menopause Review
eISSN: 2299-0038
ISSN: 1643-8876
Menopause Review/Przegląd Menopauzalny
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

without publication fees
1/2025
vol. 24
 
Share:
Send email
Share:
abstract:
Review paper

Does FIGO 2023 meet clinical needs? An analysis of challenges and limitations

Wiktor Szatkowski
1
,
Aleksandra Kmieć
2
,
Tomasz Kluz
2
,
Małgorzata Cieślak-Steć
3
,
Małgorzata Urszula Nowak-Jastrząb
1
,
Magdalena Śliwińska
3
,
Izabela Winkler
4
,
Jacek Tomaszewski
4
,
Marcin Misiek
5
,
Paweł Blecharz
1

  1. Department of Gynecologic Oncology Maria Skłodowska-Curie National Research Institute of Oncology Kraków Branch, Kraków, Poland
  2. Department of Gynecology and Obstetrics, Institute of Medical Sciences, Medical College of Rzeszów University, Rzeszów, Poland
  3. Department of III Clinic of Radiotherapy and Chemotherapy Maria Skłodowska-Curie National Research Institute of Oncology Gliwice Branch, Gliwice, Poland
  4. Second Department of Gynecologic Oncology, St. John’s Center of Oncology of the Lublin Region, Lublin, Poland
  5. Department of Gynecologic Oncology, Holy Cross Cancer Center, Kielce, Poland
Menopause Rev 2025; 24(1): 72-78
DOI: https://doi.org/10.5114/pm.2025.150063
Online publish date: 2025/04/30
View full text Get citation
 
PlumX metrics:
The International Federation of Gynecology and Obstetrics (FIGO) 2023 classification for endometrial cancer (EC) introduces significant changes by integrating molecular subtypes (POLEmut, mismatch repair deficient, p53abn, no specific molecular profile) with traditional anatomical and pathological criteria. Key updates include an expanded number of substages, the incorporation of lymphovascular space invasion (LVSI) as a prognostic factor, and a novel division of tumors into aggressive and non-aggressive categories, reflecting advancements in oncology. These updates enhance prognostic precision and inform therapeutic strategies. Non-aggressive tumors, such as low-grade endometrioid carcinomas (G1 and G2), are associated with favorable outcomes and limited invasiveness. For these cases, factors like LVSI and depth of myometrial invasion support individualized approaches, including the potential for therapy de-escalation. Aggressive tumors, including high-grade endometrioid carcinomas (G3), serous and clear cell carcinomas, and p53abn subtypes, exhibit a higher risk of recurrence and metastasis, requiring intensified treatments. However, variability in molecular and histopathological assessments poses challenges to risk stratification within this group. Despite its potential to personalize treatment, the FIGO 2023 system presents implementation challenges. Variability in assessing LVSI, sentinel lymph node ultrastaging, and molecular markers highlights the need for standardized diagnostic criteria. Additionally, tumor heterogeneity complicates classification and therapeutic decisions, necessitating more advanced diagnostic approaches. The future success of the FIGO 2023 classification depends on harmonizing diagnostic standards, improving access to molecular technologies, and validating prognostic implications through prospective studies. While this update represents a significant step forward in tailoring EC management, further refinements are required to address diagnostic and implementation challenges and improve patient outcomes.
keywords:

FIGO 2023, endometrial cancer, molecular classification, LVSI
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2025 Termedia Sp. z o.o.
Developed by Bentus.